Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 14:16:1767-1774.
doi: 10.2147/DMSO.S392684. eCollection 2023.

Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Ozge Telci Caklili  1 , Mustafa Cesur  2 , Dimitri P Mikhailidis  3 , Manfredi Rizzo  4
Affiliations
Review

Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Ozge Telci Caklili et al. Diabetes Metab Syndr Obes. .

Abstract

Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.

Keywords: bupropion/naltrexone; drugs; liraglutide; obesity; orlistat; phentermine/topiramate; semaglutide; tirzepatide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that this article has been written independently, without any financial or professional help, and only reflects their opinion. Although the authors have given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies, the industry had no role on this article. DPM has given talks, acted as a consultant or attended conferences sponsored by Amgen and Novo Nordisk. The authors report no other conflicts of interest in this work.

References

    1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;2020:1. - PubMed
    1. Kapoor N, Kalra S, Al Mahmeed W, et al. The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact. Diabetes Therapy. 2022;13(10):1723–1736. doi:10.1007/s13300-022-01311-2 - DOI - PMC - PubMed
    1. Martín‐Calvo N, Goni L, Tur JA, Martínez JA. Low birth weight and small for gestational age are associated with complications of childhood and adolescence obesity: systematic review and meta‐analysis. Obes Rev. 2022;23:e13380. doi:10.1111/obr.13380 - DOI - PubMed
    1. Tam BT, Morais JA, Santosa S. Obesity and ageing: two sides of the same coin. Obes Rev. 2020;21(4):e12991. doi:10.1111/obr.12991 - DOI - PubMed
    1. Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest. 2021;131(1). doi:10.1172/JCI140065 - DOI - PMC - PubMed